Skip to main content

Table 5 The TRAEs of combination therapy with VEGF/VEGFR inhibitors in PROC

From: Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials

TRAEs (any grade)

Pooled ES

Heterogeneity

OR[95% CI]

p

I2

p

Hypertension

4.38[1.28–14.93]

0.018

72.1%

0.003

Mucositis

3.20[1.25–8.16]

0.015

33.0%

0.225

Proteinuria

6.15[1.75–21.59]

0.005

0.0%

0.824

Diarrhea

3.14[1.36–7.25]

0.007

42.9%

0.154

Hand-foot syndrome

6.52[1.02–41.70]

0.048

76.6%

0.014

Fatigue

1.64[0.87–3.10]

0.124

61.6%

0.034

Nausea

1.36[0.72–2.54]

0.341

59.1%

0.044

Vomiting

1.74[0.76–4.02]

0.192

55.0%

0.064

Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us